Lumiquick Acquires Aoxre to Expand Global IVD and Research Capabilities
Posted on 29 Sep 2025
Oxidative stress has been linked to cellular damage involving proteins, DNA, and lipids, and it plays a role in conditions such as cardiovascular disorders, diabetes, neurodegenerative diseases (Alzheimer’s and Parkinson’s), cancer, and chronic infections. Detecting and monitoring oxidative stress biomarkers is essential for both clinical diagnostics and research, yet current tools remain fragmented and limited in reach. To address this, a major acquisition is set to expand global access to advanced diagnostic solutions and research tools.
Lumiquick Diagnostics (Santa Clara, CA, USA), a developer and manufacturer of in vitro diagnostic (IVD) tests, has acquired AOXRE LLC (Burlingame, CA, USA), which is recognized for its innovative OxisResearch product line. At the heart of the OxisResearch product line are the Bioxytech assay kits targeting oxidative and nitrosative stress biomarkers.
With this acquisition, customers can expect the full product line of oxidative stress markers and companion diagnostic assays, including Cellular Damage Monitoring, REDOX balance assessment, ELISA, and rapid test of various biological markers that are associated with the oxidation status of the human body.
This strategic acquisition marks a significant milestone for Lumiquick as it continues to expand its global footprint and product portfolio in the IVD & research industries. AOXRE’s expertise, technology, and customer relationships will be fully integrated into Lumiquick’s operations, strengthening the company’s position as a comprehensive provider of high-quality diagnostic and research tools.
“We are thrilled to welcome AOXRE into the Lumiquick Diagnostics family,” said Charles Yu, President of Lumiquick Diagnostics. “The addition of the AOXRE product line will strengthen LumiQuick’s ability to support both the clinical and research communities.”
Related Links:
Lumiquick Diagnostics
AOXRE LLC
